American Association for Cancer Research
Browse
crc-22-0259-s03.pdf (27.81 kB)

Figure S3 from Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia

Download (27.81 kB)
journal contribution
posted on 2023-04-04, 02:05 authored by Kazuharu Kamachi, Hiroshi Ureshino, Tatsuro Watanabe, Nao Yoshida-Sakai, Yuki Fukuda-Kurahashi, Kazunori Kawasoe, Toshimi Hoshiko, Yuta Yamamoto, Yuki Kurahashi, Shinya Kimura

Figure S3. BCL2 and BCL-xL levels in HL60 and KG1a following Vehicle (Cont), 1.0 mM of OR21 (OR1), 0.1 mM (HL60) or 0.5 mM (KG1a) of venetoclax and OR21 and venetoclax (OR+Ven) combination treatment. n.s. indicated not significant.

Funding

Shinnihon Foundation of Advanced Medical Treatment Research (公益財団法人 新日本先進医療研究財団)

Takeda Science Foundation (TSF)

Japan Medical Association (JMA)

MEXT | Japan Society for the Promotion of Science (JSPS)

Ohara Pharmaceuticals (Ohara)

History

ARTICLE ABSTRACT

The standard treatment for elderly patients with AML is Ven combined with HMAs. OR21, a new oral HMA plus Ven showed synergistic antileukemia effects in vitro and vivo, suggesting that the combination of OR2100 plus Ven is a promising candidate oral therapy for AML.

Usage metrics

    Cancer Research Communications

    Categories

    Keywords

    Hematological CancersLeukemiasDrug TargetsCell SignalingCell Death And Senescencebcl-2 pathways

    Licence

    CC BY

    Exports